Table 1.

Patient and control subject characteristics.

	Disease candidate (n = 22)	HCM (n = 48)		Hypertension controls (n = 50)		Healthy controls (n = 60)
			P		p		P
Age	50 ± 15	56 ± 11	0.10	55 ± 15	0.56	53 ± 17	0.78
Male gender n (%)	13 (60%)	41 (85%)	0.001	32 (64%)	0.56	35 (59%)	0.89
% White/Asian/Black	82/5/13	60/23/17	< 0.001	66/18/16	0.009	90/8/2	0.01
%TWI/deep TWI	27/73	21/79	n/a	0/0	n/a	0/0	n/a
EDV (ml)	128 ± 31	117 ± 24	0.09	144 ± 42	< 0.001	133 ± 31	0.007
ESV (ml)	31 ± 16	25 ± 10	0.06	47 ± 26	< 0.001	44 ± 14	< 0.001
SV (ml)	98 ± 21	92 ± 20	0.26	96 ± 24	0.32	89 ± 20	0.36
EF (%)	76 ± 8	79 ± 7	0.23	69 ± 11	< 0.001	68 ± 5	< 0.001
Mass (g)	156 ± 40	223 ± 69	< 0.001a	163 ± 64	0.01	123 ± 33	< 0.001
Left atrial area (cm2)	28 ± 7	27 ± 6	0.43	23 ± 4	< 0.001	20 ± 4	< 0.001
Max WT base (mm)	10 ± 1	14 ± 4	< 0.001a	11 ± 3	0.05	8 ± 1	< 0.001
Max WT apex (mm)	12 ± 1	17 ± 4	< 0.001a	6 ± 2	< 0.001	5 ± 1	< 0.001
Cavity oblit (mm)	23 ± 10	39 ± 15	< 0.001a	8 ± 5	< 0.001	4 ± 3	< 0.001
MAPSE (mm)	12 ± 3	11 ± 2	0.10	12 ± 3	0.10	13 ± 2	< 0.001
Number of antihypertensives. (0/1/2/3/4/5/6)				7/5/13/7/4/3/1

^aUnpaired T-Test vs disease candidate patients.